Skip to main content

Table 6 Summary of DVH-based analysis for the intestine in five groups

From: Escalation of radiotherapy dose in large locally advanced drug-resistant gastrointestinal stromal tumors by multi-shell simultaneous integrated boost intensity-modulated technique: a feasibility study

Groups

V20(%)

V30(%)

V40(%)

V50(%)

D195cc (cGy)

D1cc (cGy)

D2cc (cGy)

Dmean(cGy)

EUDins(cGy)

Con-IMRT

28.19

(8.70–46.80)

12.77

(2.80–21.60)

5.97

(0.50–10.4)

1.12

(0.0–2.60)

2440.40

(32.61–4430.70)

5133.89

(4918.40–5316.50)

4876.87

(3731.20–5291.10)

1425.07

(533.10–2017.30)

30.25

(21.83–33.77)

SIB10-IMRT

27.24

(8.70–43.10)

12.41

(2.70–20.50)

5.72

(0.50–9.90)

0.97

(0.0–2.10)

2485.29

(32.04–4361.40)

5113.31

(4710.40–5348.60)

4841.24

(3664.40–5291.50)

1383.79

(530.50–1953.60)

29.59

(21.09–33.44)

SIB15-IMRT

27.37

(9.30–45.0)

12.67

(2.80–21.60)

5.83

(0.60–10.10)

1.07

(0.0–2.30)

2441.37

(32.21–4387.50)

5170.90

(4897.70–5403.80)

4905.77

(3701.90–5338.90)

1404.76

(537.20–2004.70)

30.12

(22.32–33.58)

SIB20-IMRT

28.01

(8.90–43.90)

12.84

(2.80–20.90)

5.94

(0.50–11.30)

1.10

(0.0–2.20)

2439.43

(32.228–451.80

5161.34

(4723.80–5569.50)

4884.20

(3689.60–5508.40)

1422.64

(534.80–2014.10)

30.09

(21.16–34.47)

SIB25-IMRT

27.19

(9.50–43.6)

12.59

(3.10–21.00)

6.04

(0.60–11.60)

1.21

(0.0–2.70)

2497.93

(32.10–4541.00)

5233.63

(4869.70–5617.20)

4945.10

(3670.00–5523.90)

1426.23

(543.40–2018.70)

30.37

(22.14–34.48)

p-values

0.667

0.798

0.683

0.047*

0.869

0.171

0.296

0.115

0.007**

  1. Bold represented the optimal values of parameters. It displayed the trend of each parameter more plainly
  2. EUDins: the EUD of intestine
  3. *The lowest p-value of Pairwise comparisons for V50 (%): SIB10-IMRT VS SIB25-IMRT, P = 0.068
  4. **The significant differences of Pairwise comparisons for EUDins: Con-IMRT VS SIB10-IMRT, P = 0.007; SIB10-IMRT VS SIB25-IMRT, P = 0.023